Can NAD+ Cause Heart Palpitations? Evidence and Warning Signs

A faster heart rate and chest pressure have been reported during NAD+ infusions. That does not establish how often NAD+ causes a diagnosed arrhythmia, and it is not a reason to dismiss symptoms as a harmless “NAD rush.” If palpitations occur with chest pain, significant shortness of breath, fainting or near-fainting, seek emergency care—call 911 in the US ²³.

If symptoms start during an infusion, tell the supervising clinical team immediately. Do not decide from a wellness article whether to continue, increase or repeat a treatment. This page explains the evidence behind the question; our broader NAD+ side-effects guide compares routes and other reported reactions.

Featured partner

CoreAge Rx

From $93/mo

Check availabilityRead our review

Affiliate link. We may earn a commission at no extra cost to you.

Affiliate partner

Embody

NAD+ injection or nasal spray, dosing protocol published

See Embody↗

Palpitations are a symptom, not a diagnosis

Palpitations describe noticing an unusual heartbeat: pounding, fluttering, racing or a sensation of skipped beats. A person can notice this with a normal rhythm, a faster normal rhythm or an abnormal rhythm. The feeling alone cannot identify which is occurring ².

That distinction matters when interpreting a treatment testimonial. “My heart raced” is important information, but it is not an ECG diagnosis. Conversely, a clinic describing the sensation as expected does not demonstrate that a particular episode is safe. The appropriate assessment depends on the symptoms, medical history and clinical findings.

The NAD+ cardiovascular evidence review addresses proposed benefits, which are a different question from what to do about a new symptom after treatment. A cardiovascular research rationale does not rule out an adverse reaction.

What the 2026 infusion study actually reported

A retrospective study examined records from clients receiving NAD+ or NR infusions in a commercial wellness setting. NAD+ recipients reported gastrointestinal symptoms, increased heart rate and chest pressure during infusions. Symptoms in that series resolved when the infusions finished ¹.

This is preliminary tolerability evidence, not a controlled trial designed to measure the incidence of arrhythmias. The study cannot supply a reliable personal risk percentage, establish a universal safe infusion speed or show that symptoms in another patient will follow the same course. All authors were employed by the clinic operator, a relevant limitation when interpreting the report ¹.

NR and NAD+ are different compounds. A different infusion experience in that study does not mean oral NR has been proven safe for a person with an arrhythmia, or that switching products without assessment is an appropriate response. Our Niagen IV and NAD+ comparison explains the product distinction and the study’s limits.

Does every NAD-related supplement carry the same risk?

No single result can establish the risk of every formulation and route. Commercial NAD+ injections, oral NMN, oral NR and multi-ingredient “NAD boosters” are different exposures. The small infusion comparison cannot determine the frequency of palpitations after a home shot or an oral capsule.

Read the complete ingredient list. Caffeine and other substances, prescribed medicines, illness and underlying heart conditions may be relevant to a symptom assessment; timing after a new product is a clue, not proof of the cause ²³. A familiar supplement brand or a normal previous infusion does not settle a new episode.

The NMN safety article and NR side-effects review describe their own evidence. They should not be used as medical clearance to try another NAD-related product after unexplained palpitations.

When symptoms need urgent attention

Palpitations with chest pain, shortness of breath or feeling faint can indicate a problem that needs urgent care. NHS guidance identifies these accompanying symptoms as emergency warning signs; American Heart Association guidance similarly emphasizes chest symptoms, breathlessness and fainting ²³. Call the local emergency number rather than driving yourself if you may be having an emergency.

Even without those warning signs, recurrent episodes, episodes lasting more than a few minutes or symptoms in someone with known heart disease deserve medical review ³. If symptoms have stopped, describe what happened rather than assuming the absence of symptoms now proves that nothing significant occurred.

Do not use an arbitrary pulse cutoff from a supplement forum to decide whether chest pain can be ignored. The American Heart Association notes that a fast heartbeat has different causes and that simply slowing the rate can be inappropriate if it is a response to another condition ⁴. This page does not provide a home treatment or an infusion-rate adjustment protocol.

Information that helps the clinical assessment

Keep the product label and note the route, amount administered, timing and other medicines or supplements. If an infusion was underway, the treating team should document its preparation and administration details. Describe what the heartbeat felt like, how long it lasted and whether dizziness, chest discomfort or breathing changes occurred.

Clinicians may use an ECG and, for intermittent symptoms, longer monitoring to understand the rhythm ⁴. A wearable reading can be useful information to bring, but a single reassuring screen should not override significant symptoms. Ask the clinician how to handle the product before another dose rather than performing a trial re-exposure yourself.

Product quality is a separate safety question

Not every reaction after an injectable product has the same explanation. FDA has reported severe chills, shaking, vomiting and fatigue after NAD+ injectables, consistent with excessive endotoxin exposure ⁵. Those reports do not establish that endotoxin caused a particular palpitation episode. They show why product quality should be considered alongside the molecule and administration process.

The IV safety checklist explains what to ask about preparation, supervision and response to adverse symptoms. A clear pharmacy name and a supervised appointment are useful process information, but neither guarantees that a new symptom can be ignored.

The practical conclusion is to take the symptom seriously without inventing its cause. There is a published infusion tolerability signal, limited evidence about its frequency and consequences, and a well-established need to assess palpitations according to their clinical features—not their marketing label.